3 RESULTS
The screening was performed in 431 patients treated for hematological
malignancies. Forty-five patients who fulfilled the study criteria were
enrolled and are discussed henceforth. The characteristics of the 45
patients are listed in Table 1. The median duration from the end of
treatment was 15 months (IQR 8.75, 25). The median duration since the
last transfusion was 33 months (IQR: 23.5, 47.5). The patients treated
with more intensive chemotherapy (regimen B for ALL) had a greater (8.9
vs. 7.9 units) transfusion requirement as compared to those treated with
standard (regimen A for ALL) chemotherapy, though it lacked significance
(p=0.066).